Psychedelic Stocks Archives - Page 57 of 61

FridayFeb 18, 2022 1:04 pm

Study Finds That Psychedelics Can Alter Core Metaphysical Beliefs

A new study has found that psychedelic substances can alter an individual’s core beliefs about the nature of free will, consciousness and reality. The study’s findings were reported in the “Scientific Reports” journal. The researchers’ objective was to find out whether psychedelics had the capacity to change a person’s core metaphysical beliefs, because the drugs can induce spiritual encounters and transformative experiences. Metaphysical beliefs are ideas about reality’s fundamental nature. The study was carried out by a team of researchers led by Christopher Timmermann, who examined the metaphysical beliefs of participants before and after they had used psychedelics. The researchers…

ThursdayFeb 17, 2022 10:15 am

Maryland Senators File Measure to Offer Veterans Free Access to Psychedelics

Earlier this week, a group of senators in the state of Maryland filed a measure which would establish a fund that could be used to support research into the therapeutic potential of psychedelics. The bill also called for providing free access to psychedelic drugs such as ketamine, MDMA and psilocybin for military veterans with PTSD. The bill, which was sponsored by Sen. Sarah Elfreth, would create a PTSD Alternative Therapies fund. The state fund would finance studies on psychedelics through Maryland’s Department of Health as well as offer cost-free access to alternative therapies. The measure stipulates that regulators will have…

WednesdayFeb 16, 2022 3:08 pm

Advocates Challenge DEA’s Proposal to Schedule Five Psychedelic Compounds

Researchers and advocates are challenging the DEA’s proposal to classify a series of psychedelic compounds under Schedule I of the Controlled Substances Act. The Drug Enforcement Administration published a scheduling proposal in the Federal Register in January that highlights its plan to ban the following tryptamines: DiPT, 5-MeO-DET, 5-MeO-MiPT, 5-MeO-AMT and 4-OH-DiPT. The DEA wants to classify these tryptamines under the same category as drugs such as LSD, cannabis and heroin. The agency stated that before it made the proposal, it conducted its own analyses as well as considered research and recommendations from the Department of Health and Human Services,…

TuesdayFeb 15, 2022 3:08 pm

Utah House Committee Approves Measure Allowing Research on Mental Health Benefits of Psychedelics

Last week, a House committee in the state of Utah passed a measure that would establish a task force to conduct research on and give recommendations for the therapeutic potential of psychedelic substances and regulations governing their legal use. The bill, which was sponsored by Rep. Brady Brammer, was approved by the House Health and Human Services Committee in a 10-to-1 vote. The bill stipulates that the task force would be required to research and give recommendations on drugs that could assist in mental illness treatment. The drugs to be considered included controlled substances that had the potential to manage,…

MondayFeb 14, 2022 12:32 pm

What You Should Consider Before Investing in Psychedelics Space

The psychedelics industry is projected to grow at a compound annual growth rate of 14.5% in the short term, hitting $6.3 billion by 2026. Psychedelics present an attractive investment opportunity for any investors seeking to diversify their portfolio. However, like most major decisions in life, investing hard-earned money should be done with a lot of forethought and caution, especially when dealing with products that have a lot of room for growth, such as psychedelics. To help stake a profitable position in the burgeoning psychedelics space, potential investors will need to understand that experts’ expectations of psychedelics blowing up in the…

FridayFeb 11, 2022 2:03 pm

Seattle Doctor Petitions DEA to Reschedule Psilocybin

Last week, Seattle doctor Sunil Aggarwal filed a petition with the Drug Enforcement Agency (“DEA”) challenging its Schedule I classification of psilocybin, which is the primary psychoactive component of hallucinogenic mushrooms. The federal petition filed by the doctor, who specializes in end-of-life care, requests that the DEA reschedule psilocybin as a Schedule II drug given the potential it has shown in relieving symptoms of various ailments including depression and anxiety caused by a terminal disease diagnosis. The petition also highlights how decades of research have shown that psilocybin has a low potential for abuse in comparison with other substances under…

ThursdayFeb 10, 2022 1:24 pm

Activists in Michigan File Psychedelic Legalization Voter Initiative

Activists in the state of Michigan have filed a ballot measure that will legalize the possession, cultivation and sharing of psychedelic substances as well as establish a system for the spiritual and therapeutic use of psychedelics, if approved. The Students for Sensible Drug Policy, a youth-led organization, and the Michigan Chapter of Decriminalize Nature worked together on this effort. The state’s ballot initiative would legalize various entheogenic substances, including DMT, peyote, mescaline, ibogaine, psilocin and psilocybin, for individuals aged 18 and above. During a recent interview, codirector of Decriminalize Nature Michigan Myc Williams stated that the two groups were excited…

WednesdayFeb 09, 2022 1:48 pm

Study Uses Linguistic Analysis to Find Differences in Effects of Psychedelic Experiences

A new study looked into the various types of subjective experiences produced by five types of psychedelic drugs. Using computer algorithms, the researchers conducted an analysis of thousands of reports on the effects of psychedelic substances that were anonymously published. Research has shown that psychedelic substances, including psilocybin and MDMA, possess the potential to treat psychiatric conditions such as PTSD and depression. While various studies have shown that these drugs cause changes in an individual’s consciousness and perception, minimal research has been conducted quantifying the experiences linked to the consumption of these drugs. Adrian Hase, a postdoctoral researcher at the…

TuesdayFeb 08, 2022 3:49 pm

MAPS Is Developing Training Program on How to Deal with Bad Psychedelic Trips

Psychedelics sometimes cause bad trips by creating horrible scenarios for some individuals. Rick Doblin, the founder of the Multidisciplinary Association for Psychedelic Studies (“MAPS”), recently talked about difficult trips and how people could be guided through these experiences. During a recent interview, Doblin, a psychonaut and veteran psychedelic researcher, was asked whether MAPS would start a psychonaut training program based partly on principles of psychedelic harm reduction. Doblin revealed that the program, which was briefly referenced on the MAP’s website, was still being developed but would launch in various parts of North America where psychedelic substances had been decriminalized. He…

MondayFeb 07, 2022 2:09 pm

New Study Finds Weak Link Between Symptoms of Psychosis, Psychedelic Use

A new study has found that individuals who consume psychedelic substances are more likely to report symptoms associated with psychosis, which can be explained by the use of other psychoactive drugs and the presence of other mental health disorders. Psychedelics are drugs that can alter an individual’s cognition, mood and perception. This class of drugs produces hallucinogenic effects when used. Common psychedelics include psilocybin and LSD. Scientific studies conducted in the recent past have found evidence showing the possible therapeutic effects of these substances. However, few studies have looked into the potential harmful psychological effects associated with the use of…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Psychedelic Stocks